May 21, 2022 by Brian Orelli, PhDThis Biotech Stock Could See a Huge BoomThis biotech company is showing early promise.
Apr 7, 2022 by Brian Orelli, PhD, Rachel Warren, and Sanmeet Deo, CFA80% of Physicians Use This Platform, and Its Stock Could BenefitBy catering to the needs of medical professionals, Doximity could deliver in a big way.
Apr 7, 2022 by Brian Orelli, PhD10 Exciting Innovations Coming From Google HealthCutting-edge technology meets traditional healthcare.
Feb 23, 2022 by Brian Orelli, PhDWhy Biotech Stocks Fall After Positive Clinical TrialsPositive clinical results should be a good thing, right?
Feb 23, 2022 by Brian Orelli, PhDShould Biotech Investors Hold Out Hope After a Failed Clinical Trial?What happens after a trial's results are negative -- or positive?
Feb 23, 2022 by Brian Orelli, PhDInvestors: This Is the Gold Standard of Biotech TrialsTrial design may matter more than you think.
Feb 22, 2022 by Brian Orelli, PhDHow Biotech Companies Can Overcome the "Placebo Effect"Do some drug trial participants see improvements just because they're told they might?
Feb 22, 2022 by Brian Orelli, PhDOne Risk-Reward Profile Investors Should Watch in Biotech TrialsAuthor Dr. Frank David breaks down what investors should look for when it comes to trial design.
Feb 16, 2022 by Brian Orelli, PhD and Keith SpeightsNovavax Investors Can Finally Breathe a Sigh of ReliefNovavax's milestone means investors can now exhale.
Feb 16, 2022 by Brian Orelli, PhD3 Cutting-Edge, Protein-Degrader Biotech Stocks to WatchIs it time to buy a basket of biotech stocks?
Feb 16, 2022 by Brian Orelli, PhDInside Gilead's Lackluster $7.2 Billion Q4 EarningsWhy are investors unenthused with the biotech giant's earnings report?
Feb 15, 2022 by Brian Orelli, PhD and Keith SpeightsTracking Gilead's 4 Big Stories and a Lawsuit in 2022How will the cost of a settlement affect Gilead's profits over the foreseeable future?
Feb 10, 2022 by Brian Orelli, PhD and Keith Speights2 Exciting Trends That Could Shape Healthcare's FutureThese underappreciated opportunities in healthcare are worth a closer look.
Dec 1, 2021 by Brian Orelli, PhD and Keith SpeightsCathie Wood Likes Fate Therapeutics, Should You?The biotech has an interesting pipeline, but it's all early stage products.
Nov 28, 2021 by Brian Orelli, PhD and Keith SpeightsCould Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?The Swiss pharma needs to get its drug approved first.
Nov 28, 2021 by Brian Orelli, PhD and Keith SpeightsWho Would Be the Best FDA Commissioner for Biotech Investors?Robert Califf got the nod, but current acting commissioner Janet Woodcock would have made a fine choice too.
Nov 28, 2021 by Brian Orelli, PhD and Keith SpeightsVaxxinity Has a Rough Public DebutInvestors have trouble valuing the biotech's IPO.
Nov 28, 2021 by Brian Orelli, PhD and Keith SpeightsWere Compass Pathways' Clinical Trial Results Really That Bad?The biotech was priced for perfection; its data wasn't.
Nov 28, 2021 by Brian Orelli, PhD and Keith SpeightsIs Fulgent Genetics Undervalued?Whether Fulgent is a value or a value trap depends on the short-term prospects for COVID-19 and the long-term prospects for its core sequencing business.
Nov 23, 2021 by Brian Orelli, PhD and Keith SpeightsDoes It Really Matter if the Government Helped Develop Moderna's Vaccine?Investors have bigger things to worry about.
